Since immune-mediated therapies are becoming prevalent in cancer, we investigated ATV therapeutic antineoplastic activity in reference to and in combination with low-dose CP in Ehrlich solid carcinoma (ESC), a well-established murine cancer model. The gene discussed is CP; the disease is cancer.